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Abstract
This work describes the methodology used to assess a strategy for implementing clinical practice guidelines (CPG)
for cardiovascular risk control in a health area of Madrid.
Background: The results on clinical practice of introducing CPGs have been little studied in Spain. The strategy
used to implement a CPG is known to influence its final use. Strategies based on the involvement of opinion
leaders and that are easily executed appear to be among the most successful.
Aim: The main aim of the present work was to compare the effectiveness of two strategies for implementing a
CPG designed to reduce cardiovascular risk in the primary healthcare setting, measured in terms of improvements
in the recording of calculated cardiovascular risk or specific risk factors in patients’ medical records, the control of
cardiovascular risk factors, and the incidence of cardiovascular events.
Methods: This study involved a controlled, blinded community intervention in which the 21 health centres of the
Number 2 Health Area of Madrid were randomly assigned by clusters to be involved in either a proposed CPG
implementation strategy to reduce cardiovascular risk, or the normal dissemination strategy. The study subjects
were patients ≥ 45 years of age whose health cards showed them to belong to the studied health area. The main
variable examined was the proportion of patients whose medical histories included the calculation of their
cardiovascular risk or that explicitly mentioned the presence of variables necessary for its calculation. The sample
size was calculated for a comparison of proportions with alpha = 0.05 and beta = 0.20, and assuming that the
intervention would lead to a 15% increase in the measured variables. Corrections were made for the design effect,
assigning a sample size to each cluster proportional to the size of the population served by the corresponding
health centre, and assuming losses of 20%. This demanded a final sample size of 620 patients. Data were analysed
using summary measures for each cluster, both in making estimates and for hypothesis testing. Analysis of the
variables was made on an intention-to-treat basis.
Trial Registration: ClinicalTrials.gov: NCT01270022
Keywords: Primary healthcare Randomised clinical trial, Cluster analysis, Clinical practice guidelines, Cardiovascular
disease
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Background
Clinical practice guidelines (CPGs) can be defined as a
series of systematically developed recommendations
designed to help health professionals and patients take
decisions regarding the most appropriate forms of treat-
ment in specific clinical situations [1]. They are used
with the aim of preventing variability in clinical practice
via the presentation of the best scientific evidence [2].
This, however, should not be their only aim [3]; they
should also be used to solve organisational problems,
adjusting their recommendations to the preferences and
values of patients, the availability of resources, and the
concerns of managers [4]. A great many CPGs have
been produced in recent years. In 1992 the National
Library of Medicine of the USA published an exhaustive
monograph recounting the appearance of 533 between
the years of 1985 and 1992 [5], yet this can only be an
approximation to their true number. In Spain, the Guía
Salud Project collected and reviewed 425 CPGs in Feb-
ruary 2010 [6].
The evaluation of the use of CPGs in terms of health
results is not very extended in Spain. With the excep-
tion of the Programa de Actividades Preventivas y de
Promoción de la Salud (PAPPS; Program of Preventive
Activities and Health Promotion) [7], no studies on the
effectiveness of CPGs at the primary healthcare level
appear to exist. A systematic review published in the
Lancet in 1993 [8] reported that, of 59 reviewed CPGs,
none of which were used in the primary healthcare set-
ting, 55 had improved the health of patients following
their implantation. This improvement appeared to be
related to the implementation strategy used. Studies that
have assessed the impact of CPGs in the primary health-
care setting, however, show them not to have been of
benefit to patients. A review focused on primary health-
care that investigated 91 studies found only five inter-
ventions to have been of any benefit to patients [9].
In fact, only 13 actually met the inclusion criteria of
the study. The authors of this review warn of the poor
quality of the CPGs in question and their scant
implementation.
According to a review of studies on the implementa-
tion of CPGs, only 40% of health professionals actually
read them, and while 78% profess to use them the real
figure could be as low as 5% [10].
It can be inferred that the use a CPG is related to a
number of concatenated factors: it would appear impor-
tant that health professionals relate to the CPG in ques-
tion [11], that local adaptations have been made
involving people close to the potential end users, and
that guidelines are adjusted to the peculiarities of the
setting in which they are to be used. These factors facili-
tate the implementation of CPGs, improve their use, and
increase their final impact [12]. However, one of the
most important factors affecting the use of CPGs is the
implementation strategy employed [13]. No evidence is
available, however, on what night be the best implemen-
tation strategy. The classic review by Fremantle [14]
reports that the implementation of CPGs based on edu-
cational methods and using computer-based reminders
can improve use by some 15%. Certainly, however, no
studies are available on what might be the best way to
implement a CPG at the primary healthcare level in
Spain.
All bodies that propose recommendations for the pro-
duction of CPGs indicate that implementation strategies
should be included in the document’s planning. Failure
to do this is unlikely to lead to any changes in medical
practice. The diffusion methods that have given the best
results have been those designed to bring about a posi-
tive predisposition in the end user before the CPG is
presented, e.g., via the release of part of the information
so that end users might consider the need for change,
and offering them alternatives in the use of the CPG,
assuring them that it contains no strict rules to follow
but recommendations that the professional should use
adequately with each individual patient [15].
None of the above studies, however, affords conclusive
results. In this light, the present work describes the aims
and design of a project undertaken to determine the
effectiveness of a CPG implementation strategy for the
control of cardiovascular risk. A CPG for the detection
and treatment of this problem was chosen given the
important public health burden of heart disease, and
because, despite the potential benefits of using CPGs in
this area, their true use by primary care practitioners
has room for improvement [16].
Aims
The main aim of this work was to compare the effec-
tiveness of 1) a proposed strategy based on an educa-
tional method involving the participation of opinion
leaders with 2) the usual method of dissemination, for
implementing a locally adapted CPG for the control of
cardiovascular risk among the primary healthcare teams
of a health area in Madrid.
Methods
This study (ClinicalTrials.gov Identifier number:
NCT01270022) was a controlled, blinded community
intervention study, randomised by clusters (primary
healthcare centres). This design was chosen since the
intervention necessarily involved primary healthcare
teams. Twenty one health centres of the Madrid A2 Pri-
mary Healthcare Area were randomly assigned to the
normal dissemination or proposed implementation strat-
egy arms of the study (10 to the former and 11 to the
latter). These 21 health centres (clusters) provide care to
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373,495 people. The two strategies were aimed at the
healthcare teams (doctors and nurses) of each partici-
pating centre. The effect of the two strategies on 1) the
recording of cardiovascular risk data in the clinical his-
tories of the patients, 2) the control of cardiovascular
risk factors, and 3) the incidence of cardiovascular
events, was determined.
Intervention
The CPG used in this study was a local adaptation of
the different cardiovascular risk guidelines established
by healthcare professionals working in both the primary
and hospital settings. The dissemination of the CPG to
the normal dissemination group was via the method tra-
ditionally used in the health area, i.e., sending it by mail
to all healthcare professionals and the provision of an
information workshop lasting 2 h. The strategy used
with the implementation group involved an educational
model based on the involvement of opinion leaders plus
the method used with the normal dissemination group.
The implementation strategy, which was aimed at the
doctors and nurses employed at the health centres,
involved 4 × 1 h education sessions. These were masked
within the normal staff meeting held at each centre to
avoid the undertaking of the present study becoming
known. The sessions were led by trained personnel
recognised as leaders of opinion by the healthcare pro-
fessionals at the centres - a normal practice in these ses-
sion. The first session was delivered by a doctor and a
nurse, members of the team that coordinated the
authoring of the CPG. During this session the metho-
dology used to produce the CPG was explained, under-
lining the importance of stratifying the cardiovascular
risk of patients attending primary healthcare clinics. In
the second session, a nurse from the health area (one of
the authors of the CPG) discussed with the health cen-
tre staff the diagnosis, classification and treatment of
low risk patients, screening techniques for different car-
diovascular risks, and methods for evaluating these risks.
In the third session, a physician author of the CPG with
prestige amongst his/her peers discussed the pharmaco-
logical recommendations associated with cardiovascular
risk factors, and the diagnosis, treatment and classifica-
tion of high risk patients. In the final session, a physi-
cian author (an internal medicine specialist) from the
Hospital Universitario de la Princesa, discussed referral
criteria and the coordination proposals included in the
CPG.
Study stages
The study was divided into three stages. 1) Preliminary
work. In July 2004, a cross-sectional study was underta-
ken to determine the status of the cardiovascular infor-
mation in the selected patients’ records. This involved
the collection of the data required to determine the dif-
ferent risk factors recorded, the degree of control of car-
diovascular risk factors, and the collection of other
information required for the present study. 2) The inter-
vention. This intervention took place between February
and April 2005. One year later (April 2006) a second
cross-sectional study was undertaken to determine the
effect of the two strategies on the calculation of cardio-
vascular risk, and the control of these risk factors. 3)
Follow-up. This phase involved a third cross-sectional
study to determine the effect of the intervention on
health results (cardiovascular events and the control of
cardiovascular risk factors) at five years.
Data collection
The medical records of all patients aged 14 years and
older who according to their medical cards, belonged to
the studied health area, were collected. The initial sub-
jects to be included were selected by random sampling
weighted by the size of the population assigned to each
health centre (Figure 1). This step was undertaken to
ensure that the final sample would be independent of
the aging of the population of each centre. Among these
selected subjects, those aged 45 years and over were
chosen to be the final study subjects. This age was cho-
sen since it is that given priority in community interven-
tion studies on cardiovascular risk, both in men and
women [17]. Patients with no medical history available
were classified as non-locatable. Those patients whose
medical histories did not mention their age or sex were
excluded, as were those who had not visited their health
centre in the previous year.
To ensure blindness in the assessment of the effective-
ness of the intervention (evaluation of the above vari-
ables in clinical records), the evaluators were not told to
which arm of the study the patients belonged. The team
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Figure 1 Patients Flow chart: number of patients finally
studied and their distribution.
Rodríguez-Salvanés et al. BMC Family Practice 2011, 12:21
http://www.biomedcentral.com/1471-2296/12/21
Page 3 of 6
members whose job it was to analyse the results did not
know this information either.
Variables measured
The impact of the intervention was measured in terms
of registry variables (cardiovascular risk data in the clini-
cal histories of the patients), intermediate variables (the
control of cardiovascular risk factors at one and five
years) and health results (the incidence of cardiovascular
events at five years). At one year, the effect of the two
strategies was determined by calculating the difference
in the proportions of overall cardiovascular risk calcula-
tions before and after the intervention, or the explicit
recording of all the variables needed for such calcula-
tions to be made (blood pressure, fasting glycaemia, fast-
ing cholesterol, use of tobacco, age and sex). Blood
pressure was deemed well controlled when the systolic
pressure was ≤ 140 mmHg and the systolic blood pres-
sure ≤ 90 mmHg; this was reduced to 130/80 mmHg if
the patient was diabetic. Good control of glycaemia was
deemed present when fasting blood sugar was < 126
mg/dl. The control of dyslipidaemia was considered
good when total cholesterol was < 200 mg/dl, or LDL-
cholesterol was < 100 mg/dl in diabetics.
At five years, the differences in health variables
between the arms of the study, i.e., percentage of cardio-
vascular events (acute myocardial infarction, angina,
stroke and the need for revascularization), the cardiovas-
cular mortality and overall mortality, were determined.
Since each of the health centres had different character-
istics, data on a series of potential confounding factors
(characteristics of the health centre and their staff) were
recorded.
Sample size
The unit of randomisation taken into account was not
each patient but each health centre. The number of cen-
tres included in the study was 21 - all those in the stu-
died health area. The sample of patients finally selected
at any centre was proportional to the size of the popula-
tion ascribed to that centre. The required sample size
was determined by assuming that the implantation of
the CPG could be regarded as successful if a 15%
increase in the recording of the study variables were
seen in the proposed implementation strategy arm, i.e.,
increasing from 40% to 55%. To show this effect, the
sample size needed to reject the null hypothesis could
have been calculated in the normal way [18] for the
comparison of two proportions. For an alpha of 0.05
and beta of 0.20, the necessary sample size would have
been n = 173*2 = 346 patients. However, designs invol-
ving randomisation by clusters with a fixed number of
clusters requires a larger sample in order to take into
account the design effect (DE). According to Campbell
[19], DE = 1 + (m - 1) · r, where m is the mean size of
the cluster and r the intracluster correlation coefficient
(ICC). Since 346 patients would be needed if sampling
were not via clusters, and since the study involved 21
health centres, the mean sample size per cluster (m) (if
clusters are used) becomes 16.5 (346 patients across 21
centres).
Given that reported by Adams et al. [20], an ICC of
0.032 was assumed for the majority of variables exam-
ined. The DE therefore became: DE = 1 + (m-1) · r =
1.5. The corrected sample size was therefore: n´= n · ED
= 346 · 1.5 = 517. Assuming a loss rate of 20%, the final
sample size would be 620 patients randomly assigned to
the two arms of the study (10 clusters in the normal dis-
semination group, and 11 in the proposed implementa-
tion strategy group). This sample size was adjusted for
the fact that, in the studied health area, some 47% of
the population is over 45 years of age. The total number
of medical histories to examine was therefore at least
1170 for both arms together. Figure 1 shows the num-
ber of patients finally studied and their distribution.
Statistical analysis
The use of a design involving randomisation by clusters
conditions the statistical methods that can be used.
Although some authors [21] propose performing indivi-
dual level analysis when the number of clusters is >20,
there is no consensus [22], and since the present num-
ber was 21 a more conservative approach (cluster level
analysis) was followed. The overall impact of the inter-
vention was determined by comparing the means of the
variables measured in each cluster using the t-test.
Although the assumptions of homoscedasticity and nor-
mal distribution may not be satisfied, this is not so
important since the t-test is robust to such departures
[23]. Since the cluster sizes were not similar, the t-test
was weighted for each cluster j by wj = nj1·nj2/nj1+nj2
(where 1 and 2 are moments before and after the inter-
vention respectively) [24]. The calculation of the confi-
dence intervals also required weighting in the same way.
Analysis was on an intention-to-treat basis. All p values
reported were two-tailed. STATA v.8.0 software was
used for all calculations.
Discussion
Cardiovascular risk was chosen as an indicator of
change for three reasons: its measurement is essential in
the reduction of cardiovascular events, its measurement
depends completely on good practice on the part of
medical professionals, and it is not influenced by patient
attitude or any medical professional/patient or patient/
healthy system relationship. The present strategy is rela-
tively simple and, if shown to provide reliable results,
could be used in other settings in which the use of
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more complex designs (see for example 25) may not be
viable.
A number of reasons dictated that randomisation by
clusters be used rather than simple randomisation,
despite the lower statistical power of this method [26].
Firstly, since all the healthcare staff of each centre were
involved, it avoids the contamination that might occur if
simple randomisation were followed. Secondly, although
the intervention was aimed at the staff, the assessment
took the form of an audit of the patients’ clinical
records. Finally, since randomisation was by clusters,
analysis by clusters was therefore necessary. In recent
years, the method employed in this work has become
standard in the assessment of the effects of health inter-
ventions (implementation research) [27].
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